Genmab — Januar 2018
-
super dårlig til TA, men kan man betegne udviklingen i GEN som "cup a
nd handle"? -
@laerlingen jeg mener det ikke, den er for kort og ujævn
-
øv øv..men tak
-
I don't know TrinityDelta, but his is their research on BergenBio for those interested http://www.trinitydelta.org/bergenbio . At some point they do state: "while the most advanced antibody-based product in clinical development is
Genmab’s ADC, Humax-AXL-ADC." -
$373.000 for en CAR-T behandling - JUNO aktionærerne kan puste ud nu og sende sorteper videre https://www.bloomberg.com/gadfly/articles/2018-01-17/celgene-needs-a-boost-but-juno-therapeutics-isn-t-it?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo
-
Bulder - hvordan gives Humax-AXL-ADC. sc eller iv?
-
Tak. 30 minutter er trods alt forholdsvis kort tid for iv, specielt når man sammenligner med dara.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind